Treatment of Erectile Dysfunction I

• Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF (Last Observation Carried Forward) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  Erectile Function domain: 0 (poor) - 5/(good) scoring scale for each of 6 questions (0-30/max/good). Over last month: How often were you able to get an erection during sex? When you had erections with stimulation, how often were your erections hard enough for penetration? When you attempted intercourse, how often were you able to penetrate your partner? How often were you able to maintain your erection after penetrating your partner? How difficult was it to maintain your erection to completion of intercourse? How do you rate your confidence that you can get & keep your erection?
• Change in Sexual Encounter Profile (SEP), Question 2, Change From Baseline to Overall Study/Weeks 1-12, mITT [ Time Frame: Baseline and Weeks 1 - 12 ] [ Designated as safety issue: No ]
  Question 2 SEP: Were you able to insert your penis into your partner's vagina? yes/no response; no scale. Measured percent yes responses during baseline and compared with percent yes responses during overall treatment period.
• Change in SEP Question 3, Change From Baseline to Overall Study/Weeks 1-12, mITT [ Time Frame: Baseline and Weeks 1 - 12 ] [ Designated as safety issue: No ]
  Question 3 SEP: Did your erection last long enough for you to have successful completion of intercourse? yes/no response; no scale. Measured percent yes responses during baseline and compared with percent yes responses during overall treatment period.

• Global Assessment Questionnaire (GAQ), While Using the Study Medication, Did You Feel That Your Erections Improved? (Yes Responders), Week 12/Final Visit, mITT Population [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
• Change From Baseline to Week 12/Final Visit in Mean Patient Self-Assessment of Erection (PSAE), mITT Population [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
  PSAE, select one of the following: 1) no evidence of any tumescence or erection, 2) partial tumescence or erection (not likely to be sufficient for penetration), 3) great tumescence or erection sufficient for vaginal penetration, but not fully rigid, 4) full rigidity, scale 1/no evidence of erection (min) to 4/full erection (max)
• Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Derived Score, Subject Version, Week 12/ Final Visit, LOCF, mITT Population [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
  EDITS-derived score is sum of responses, range 0/bad-4/good, 11 questions, standardized to scale of 100: How satisfied w/treatment? How likely to continue?, During past 4 wks, has treatment met expectations? How easy to use? How satisfied w/how quickly it works? How long it lasts? How confident made you feel to engage in sex? How satisfied do you believe your partner is with treatment effects? How does your partner feel about your continuing use? How natural did process of achieving erection feel? Compared to before erection problem, how natural did erection feel in terms of hardness?
• Change in Satisfaction of Intercourse Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  Satisfaction of Intercourse domain: 0 (poor) - 5/(good) scoring scale for each of 3 questions (0-15/good). Over last month: How many times have you attempted sexual intercourse? When you attempted intercourse, how often was it satisfactory for you? How much have you enjoyed sexual intercourse?
• Change in Orgasmic Function Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  Orgasmic Function domain: 0 (poor) - 5/(good) scoring scale for each of 2 questions (0-10/good). Over last month, when you had sexual stimulation or intercourse how often did you ejaculate? When you had sexual stimulation or intercourse how often did you have the feeling of orgasm (with or without ejaculation)?
• Change in Sexual Desire Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  Sexual Desire domain: 1 (poor) - 5/(good) scoring scale for each of 2 questions (2-10/good). Over last month, how often have you felt sexual desire? How would you rate your level of sexual desire?
• Change in Overall Satisfaction Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  Overall Satisfaction domain: 1 (poor) - 5/(good) scoring scale for each of 2 questions (2-10/good). Over last month, how satisfied have you been with your overall sex life? How satisfied have you been with your sexual relationship with your partner?
• Change in SEP Question 1, Change From Baseline to Overall/Weeks 1-12, mITT [ Time Frame: Baseline and Weeks 1 - 12 ] [ Designated as safety issue: No ]
  Question 1 SEP: Were you able to achieve at least some erection (some enlargement of the penis)? yes/no response. Measured percent yes responses during baseline and compared with percent yes responses during overall treatment period.
• Change in SEP Question 4, Change From Baseline to Overall Study/Weeks 1-12, mITT [ Time Frame: Baseline and Weeks 1 - 12 ] [ Designated as safety issue: No ]
  Question 4 SEP: Were you satisfied with the hardness of your erection? yes/no response. Measured percent yes responses during baseline and compared with percent yes responses during overall treatment period.
• Change in SEP Question 5, Change From Baseline to Overall/Weeks 1-12, mITT [ Time Frame: Baseline and Weeks 1 - 12 ] [ Designated as safety issue: No ]
  Question 5 SEP: Were you satisfied with this overall sexual experience? yes/no response. Measured percent yes responses during baseline and compared with percent yes responses during overall treatment period.

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).

• Drug: Udenafil
  Tablets via oral administration before an attempt at sexual intercourse.
• Drug: Placebo
  Tablets via oral administration before an attempt at sexual intercourse.

• Placebo Comparator: Placebo
  Intervention: Drug: Placebo
• Experimental: Udenafil 50 mg
  Intervention: Drug: Udenafil
• Experimental: Udenafil 100 mg
  Intervention: Drug: Udenafil
• Experimental: Udenafil 150 mg
  Intervention: Drug: Udenafil

Inclusion Criteria:

• Male, at least 19 years of age
• Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
• History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
• Partner is not pregnant or lactating

Exclusion Criteria:

• History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
• Cardiac arrhythmias requiring antiarrhythmic treatment
• Symptomatic congestive heart failure
• Taking nitrate medication in any form
• Uncontrolled diabetes (HbA1c ≥ 13%)
• Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
• Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®